Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000929638-26-000626·Prelude Therapeutics Inc
Schedule 13G ownership disclosure
Prelude Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 74065P101
Event date: 2025-12-31
- Filing-level shares
- 6,745,647
- Percent of class
- 13.15%
- Vaddi Krishna
Shares: 6,745,647 · Class: 13.15%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-26-000626
- Form type
- SCHEDULE 13G/A
- Filer
- Prelude Therapeutics Inc
- CIK
- CIK 1678660
- Filed
- Feb 13, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership